REFERENCES
- Sertie J. A. A., Zanini A. C., Oga S. Serum levels of different formulations of oxytetracycline in adult healthy volunteers. Cur. Ther. Res 1985; 38(6)922–930
- Brice G. W, Hammer H. F. Therapeutic nonequivalence of oxytetracycline capsules. JAMA 1969; 208(7)1189–1190
- Groves M. J. Solution tests on generic brands of oxytetracycline tablets. Pharm. J April 14, 1973; 318–319
- Jones T. M., Risdall P. C., Frier M. The equivalence of oxytetracycline BP. J. Pharm. Pharmacol 1974; 26: 116P
- Burger A., Ratz A. W., Brox W. Die polymorphen Arzneistoffe des Europäischen Arzneibuches, 3—Mitt [1]: Oxytetracyclinhydrochlorid. Pharm. Acta Helv 1986; 61(4)98–105
- Esezebo S., Pilpel N. Formulation factors affecting strength and dissolution of uncoated oxytetracycline tablets. J. Pharm. Sci. 1977; 66(6)852–858
- Lee K. C., Hersey J. A. Oxytetracycline tablet formulations: preformulation stability screening using differential thermal analysis. J. Pharm. Pharmacol 1977; 29: 515–516
- Remon J. P., Van Severen R., Braeckman P. Interpretation of thermograms of oxytetracycline-excipient mixtures. J. Pharm. Pharmacol 1978; 30: 204
- The British Pharmacopoeia. Her Majesty's Stationery Office, London 1988
- U.S. Pharmacopeial Convention. The United States Pharmacopoeia 23/The National Formulary 18. Author, Rockville, MD 1995
- Merck and Company. The Merck Index. 12th ed., Merck and Company, Rahway, NJ 1996
- Allen T. Particle Size Measurement. 4th ed., Chapman and Hall, London 1990